MEK1/2, c-Myc:MAX, and Polycomb Regulation of TERT in Human Pluripotent Stem Cells

Study Background and Research Question

Telomerase, composed of the TERT catalytic subunit, is essential for maintaining telomere length and ensuring the long-term proliferative capacity of human pluripotent stem cells (hPSCs). While telomerase activation is tightly regulated during embryogenesis and becomes restricted to stem cell compartments, the precise mechanisms governing TERT expression in normal human stem cells remain incompletely understood. Previous research established that MAPK signaling pathways, particularly MEK1/2 and ERK1/2, are crucial for self-renewal in stem cells and may influence TERT transcription. However, the chromatin-level interplay between these kinases, transcription factors such as c-Myc:MAX, and polycomb group repressors (notably PRC2 and its catalytic subunit EZH2) had not been fully delineated. The current study (Kotian et al., 2024) addresses the key question: How do MEK1/2 kinases and c-Myc:MAX complexes modulate polycomb-mediated repression of TERT in hPSCs?

Key Innovation from the Reference Study

The principal innovation of this work lies in mapping a functional axis whereby MEK1/2 kinases cooperate with c-Myc:MAX to prevent polycomb (PRC2/EZH2)-mediated silencing of TERT. The authors demonstrate that inhibition of MAPK signaling leads to the accumulation of the repressive histone mark H3K27me3 at the TERT promoter, reduced TERT transcription, and a concurrent loss of the activating mark H3K27ac. Moreover, they show that disrupting c-Myc:MAX dimerization similarly results in increased H3K27me3 and reduced TERT expression, highlighting this complex's role in safeguarding TERT from polycomb repression. These findings provide a mechanistic framework linking kinase signaling, transcription factor complexes, and the dynamic regulation of epigenetic marks at a developmentally critical gene.

Methods and Experimental Design Insights

The study employed a comprehensive approach using human embryonic stem cells (hESCs) as the model system. Pharmacological inhibitors targeting MEK1/2 and ERK1/2 were used to dissect the MAPK pathway's contribution to TERT regulation. Quantitative RT-PCR assessed TERT mRNA levels following kinase inhibition. Chromatin immunoprecipitation (ChIP) assays measured the enrichment of H3K27me3 and H3K27ac at the TERT promoter, providing locus-specific insights into chromatin state changes. The team further used a c-Myc:MAX dimerization inhibitor to probe the role of this transcription factor complex, examining both histone modification and TERT expression outcomes. Additionally, pharmacological inhibition of PRC2 was employed to test whether polycomb activity was necessary for the observed repression of TERT upon MEK inhibition.

Protocol Parameters

• Kinase inhibitor treatment: Apply MEK1/2 or ERK1/2 inhibitors to hESC cultures for 24–48 hours to assess effects on TERT mRNA and chromatin marks.
• c-Myc:MAX dimerization inhibitor: Use low concentrations for short durations (e.g., 6–24 hours) to specifically disrupt c-Myc:MAX function and monitor rapid chromatin changes.
• ChIP assay conditions: Cross-link chromatin, immunoprecipitate with specific antibodies against H3K27me3 or H3K27ac, and perform qPCR targeting the TERT promoter region.
• PRC2 inhibition for rescue: Co-treat with a PRC2 inhibitor to determine if TERT repression by MEK inhibition is polycomb-dependent.

Core Findings and Why They Matter

Inhibition of MEK1/2 or ERK1/2 resulted in a pronounced decrease in TERT transcription in hESCs, as confirmed by qRT-PCR (Kotian et al., 2024). ChIP assays revealed a significant accumulation of H3K27me3—a hallmark of polycomb-mediated gene silencing—at the TERT promoter. This shift was accompanied by a reduction in the activating mark H3K27ac, indicating a switch to a transcriptionally repressive chromatin state. Notably, inhibition of the PRC2 complex partially rescued TERT expression, directly linking polycomb activity to the observed transcriptional repression.

Further, the study found that MEK/ERK inhibition reduced c-Myc levels—an established regulator of TERT. Disrupting c-Myc:MAX dimerization independently led to increased H3K27me3 at the TERT promoter and a sharp decrease in TERT mRNA. This suggests that c-Myc:MAX acts locally to prevent polycomb deposition, thereby sustaining TERT expression in pluripotent cells. These results provide a mechanistic explanation for how pluripotency-associated signaling pathways interface with epigenetic repression machinery to maintain telomerase activity, a process vital for stem cell maintenance and potentially relevant to regenerative medicine and cancer biology.

Comparison with Existing Internal Articles

Several internal resources have previously detailed the role of selective EZH2 inhibitors, such as GSK343, in dissecting polycomb-mediated gene repression. For instance, "GSK343: Selective EZH2 Inhibitor Transforming Epigenetic..." highlights how GSK343 enables precise manipulation of PRC2-mediated H3K27 trimethylation, facilitating studies on stem cell and cancer epigenetics. The current reference study extends these concepts by directly linking MEK/ERK signaling and c-Myc:MAX function to PRC2/EZH2-mediated regulation of TERT—a chromatin-level insight that complements the practical utility of GSK343 in mechanistic dissection. Similarly, articles such as "GSK343: Selective EZH2 Inhibitor Empowering Epigenetic Ca..." and "GSK343: Potent, Selective EZH2 Inhibitor for Epigenetic C..." emphasize the application of GSK343 in studying histone H3K27 trimethylation inhibition and PRC2 pathway interrogation. The present research uniquely clarifies how upstream kinase and transcription factor networks modulate this pathway at a key developmental gene, thus providing a richer context for deploying EZH2 inhibitors in experimental workflows.

Limitations and Transferability

While the study robustly establishes a mechanistic connection between MEK/ERK signaling, c-Myc:MAX, and polycomb repression of TERT in hESCs, several limitations should be noted. The findings are based on in vitro stem cell models, which, although biologically relevant, may not fully recapitulate the dynamic regulation occurring in vivo during embryogenesis or tissue regeneration. The pharmacological inhibitors used, while specific, may exert off-target effects that warrant further validation using genetic perturbation approaches. Additionally, the extent to which these mechanisms operate in adult stem cell compartments or in cancer cells with altered telomerase regulation remains to be fully explored. Transferability to differentiated or disease contexts, such as cancer or aging tissues, should thus be approached with careful experimental design.

Research Support Resources

For researchers aiming to further dissect the role of polycomb-mediated repression in TERT regulation or broader epigenetic cancer research, selective tools such as GSK343 (SKU A3449) are available. GSK343 is a potent, cell-permeable EZH2 inhibitor that enables targeted inhibition of H3K27me3 deposition, facilitating mechanistic studies of PRC2 function in gene regulation workflows. According to the product information, it is best suited for in vitro applications and can be integrated into experimental pipelines investigating chromatin regulation in stem cells or cancer models. APExBIO supplies GSK343 as a solid, with storage and solubility parameters optimized for laboratory use.